RxDoctor Payments Data

Joseph Deluca, MD

Internal Medicine · Middlebury, CTNPI 1629090071

Payments from drug & device makers

$11,789in general payments, 2019–2025

Across 707 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Bayer$1K
  • Pfizer$891
  • Amarin Pharma, Inc.$867
  • Boehringer Ingelheim$697
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$120%
  • Food & beverage$11,69499%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)124$1,632
Novo Nordisk86$1,333
Bayer60$1,188
Pfizer64$891
Amarin Pharma, Inc.52$867
Boehringer Ingelheim31$697
GSK38$658
Lilly USA, LLC25$461
Amgen17$331
Merck19$281
Exact Sciences14$278
Takeda Pharmaceuticals U.S.A., Inc.16$257
Otsuka America Pharmaceutical, Inc.19$257
AstraZeneca13$252
Abbott12$237
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$227
Astellas Pharma US Inc7$142
Johnson & Johnson9$139
Lundbeck LLC6$121
Idorsia Pharmaceuticals US Inc5$97
Xeris Pharmaceuticals, Inc.5$90
Novartis5$82
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$77
Phathom Pharmaceuticals, Inc.5$76
Scilex Pharmaceuticals Inc.1$64
Sunovion Pharmaceuticals Inc.8$64
E.r. Squibb & Sons, L.L.C.3$58
Medtronic(3 entities)3$55
Neurocrine Biosciences, Inc.2$54
Axsome Therapeutics, Inc.2$49
Paratek Pharmaceuticals, Inc.2$42
Biohaven Pharmaceutical Holding Company Ltd.2$41
UCB, Inc.1$41
Endo Pharmaceuticals Inc.2$40
Sanofi Pasteur Inc.2$33
Irhythm Technologies, Inc.1$32
Intra-sana Laboratories2$31
Strongbridge US Inc.2$31
Therapeuticsmd, Inc.2$31
Genentech USA, Inc.2$30
Optinose US, Inc.1$26
MDD US Operations, LLC1$25
Insightec,inc1$25
Sumitomo Pharma America, Inc.1$25
Eisai Inc.1$23
Collegium Pharmaceutical, Inc.1$22
Shire North American Group Inc1$22
Shield Therapeutics Inc1$21
Ardelyx, Inc.1$21
Regeneron Healthcare Solutions, Inc.1$20
Phadia US Inc.1$20
Radius Health, Inc.1$19
Johnson & Johnson Surgical Vision, Inc.1$18
Corcept Therapeutics1$18
Sanofi-aventis U.S. LLC1$16
Ultragenyx Pharmaceutical Inc.1$16
Teva Pharmaceuticals USA, Inc.1$15
Nabriva Therapeutics, PLC1$14
Alfasigma USA, Inc.1$13
Avanir Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,789 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$110,941
Medicare patients
359
Services billed
5,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban282$127,708
OzempicSemaglutide85$107,711
JanuviaSitagliptin Phosphate76$90,137
JanumetSitagliptin Phos/Metformin Hcl78$65,731
JardianceEmpagliflozin61$50,032
MounjaroTirzepatide38$39,930
TrulicityDulaglutide32$32,801
Tresiba Flextouch U-100Insulin Degludec40$28,960
MyrbetriqMirabegron89$24,158
LinzessLinaclotide27$23,309
CreonLipase/Protease/Amylase20$17,427
XareltoRivaroxaban11$16,096
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$13,919
FarxigaDapagliflozin Propanediol16$13,444
GemtesaVibegron53$13,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$281$155,868154 claims
PfizerEliquis$891$127,708282 claims
Novo NordiskOzempic, Rybelsus$1,333$118,19296 claims
Lilly USA, LLCMounjaro, Trulicity$461$72,73170 claims
Boehringer IngelheimJardiance$697$50,03261 claims
AbbVieLinzess, Creon, Synthroid$1,632$46,239105 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$658$27,45844 claims
Astellas Pharma US IncMyrbetriq$142$24,15889 claims
Johnson & JohnsonXarelto$139$16,09611 claims
AstraZenecaFarxiga$252$13,44416 claims
Sumitomo Pharma America, Inc.Gemtesa$25$13,36253 claims
UCB, Inc.Neupro$41$8,80021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Middlebury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →